Dublin, Dec. 06, 2024 (GLOBE NEWSWIRE) — The “Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market: Focus on Method, Platform, End User, Application, and Country – Analysis and Forecast, 2023-2033” report has been added to ResearchAndMarkets.com’s offering.
The Asia-Pacific NIPT market was valued at $659.2 million in 2023 and is expected to reach $2.76 billion by 2033, registering a CAGR of 15.43% during the forecast period 2023-2033.
The adoption of supportive healthcare policies, the growing inclusion of screening procedures in insurance coverage, ongoing technological advancements, the expansion of commercial opportunities throughout the region, and the growing preference for non-invasive testing methods among expectant parents and healthcare providers are the main factors propelling the APAC NIPT market.
The market for non-invasive prenatal testing (NIPT) in Asia-Pacific is expanding significantly due to increased healthcare spending in the region and growing knowledge of sophisticated prenatal screening techniques. Because of its great accuracy, safety, and non-invasiveness, NIPT-a ground-breaking technology that examines cell-free fetal DNA from maternal blood-is becoming more and more popular. During pregnancy, it is frequently used to identify chromosomal abnormalities such Patau syndrome, Edwards syndrome, and Down syndrome.
Growing maternal age, the use of sophisticated genetic technologies, and the need for accurate and timely prenatal diagnostics are driving the market’s growth. The adoption of NIPT is being further supported by the expansion of insurance coverage for prenatal care and the implementation of healthcare reforms in many Asia-Pacific nations.
The market’s major players are concentrating on creating affordable testing solutions to serve the region’s diverse population and range of income levels. Partnerships between international corporations and regional healthcare providers are increasing awareness and accessibility, especially in developing nations.
As prenatal health awareness rises and healthcare infrastructure improves, the APAC NIPT market is expected to grow rapidly. It will be crucial in improving maternal and fetal health outcomes throughout the area.
Market Segmentation:
Segmentation by Application
- Trisomy Detection
- Microdeletion Detection
- Sex Chromosome Aneuploidy Detection
- Others
Segmentation by End User
- Hospitals
- Diagnostic Laboratories
- Others
Segmentation by Platform
Segmentation by Method
Segmentation by Country
- China
- India
- Japan
- Rest-of-Asia-Pacific
Report Scope:
Workflow/Innovation Strategy: The Asia-Pacific NIPT market (by application) has been segmented into detailed segments of the application of NIPT based on applications, including trisomy detection, microdeletion detection, sex chromosome aneuploidy detection, and others.
Growth/Marketing Strategy: Constant advancement and innovation to enhance performance and efficiency can enabled prominent players to command premium prices while maintaining growth in revenue and volume.
Competitive Strategy: Key players in the Asia-Pacific NIPT market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Asia-Pacific NIPT market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
Some prominent names established in this market are:
- BGI Genomics
- Annoroad Gene Technology
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 68 |
| Forecast Period | 2023 – 2033 |
| Estimated Market Value (USD) in 2023 | $659.2 Million |
| Forecasted Market Value (USD) by 2033 | $2760 Million |
| Compound Annual Growth Rate | 15.4% |
| Regions Covered | Asia Pacific |
Key Topics Covered:
1 Markets
1.1 Trends: Current and Future Impact Assessment
1.1.1 Increasing Strategic Partnerships and Alliances between Market Players
1.1.2 Expanding Applications in NIPT Products
1.2 Supply Chain Overview
1.3 Research and Development Review
1.4 Regulatory Landscape
1.5 Reimbursement Scenario
1.6 Market Dynamics Overview
1.6.1 Market Drivers
1.6.1.1 High Incidence of Genetic Disorders
1.6.1.2 Rising Maternal Age
1.6.1.3 Increasing Number of Reimbursement Policies toward Genetic Coverage
1.6.1.4 Increased Emphasis on Early Detection and Prevention
1.6.2 Market Restraints
1.6.2.1 Stringent Regulatory Guidelines and Ethical Hurdles
1.6.2.2 Lack of Awareness Regarding NIPT
1.6.2.3 Limitations and Considerations in Non-Invasive Prenatal Testing
1.6.3 Market Opportunities
1.6.3.1 Leveraging the Opportunities Arising from the Growing Markets in Asia
1.6.3.2 Increasing Focus on Non-Invasive Pre-Implantation Genetic Testing (niPGT)
2 Regions
2.1 Drivers and Restraints
2.2 Regional Summary
2.3 Asia-Pacific
3 Markets – Competitive Benchmarking & Company Profiles
3.1 Competitive Landscape
- BGI Genomics
- Annoroad Gene Technology
For more information about this report visit https://www.researchandmarkets.com/r/a47pu2
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Asia-Pacific Non-Invasive Prenatal Testing (NIPT) Market
